Efficacy and safety of ezetimibe 40 mg vs. ezetimibe 10 mg in the treatment of patients with homozygous sitosterolaemia

International Journal of Clinical Practice

Volumn 62, Issue 7, 2008, Pages 995-1000

  Musliner, T ^a   Cselovszky, D ^a   Sirah, W ^a   McCrary Sisk, C ^a   Sapre, A ^a   Salen, G ^b   Lutjohann D ^c   Von Bergmann, K ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAMPESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SITOSTEROL; STEROL;

ACHILLES TENDON; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOT RADIOGRAPHY; GAS LIQUID CHROMATOGRAPHY; HUMAN; INBORN ERROR OF STEROID METABOLISM; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SITOSTEROLEMIA; STATISTICAL SIGNIFICANCE; STEROID BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPID METABOLISM, INBORN ERRORS; MALE; MIDDLE AGED; SITOSTEROLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 44849126987     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01786.x     Document Type: Article

References (32)

1. Patel SB, Salen G, Hidaka H et al. Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. J Clin Invest 1998 102 : 1041 4.
2. Berge KE, Tian H, Graf GA et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000 290 : 1771 5.
3. Lee M-H, Lu K, Hazard S et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001 27 : 79 83.
4. Lu K, Lee M-H, Hazard S et al. Two genes that map to the STSL locus cause sitosterolemia: Genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8 respectively. Am J Hum Genet 2001 69 : 278 90.
5. Salen G, Shefer S, Nguyen L et al. Sitosterolemia J Lipid Res 1992 33 : 945 55.
6. Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974 53 : 1033 43.
7. Salen G, Horak I, Rothkopf M et al. Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis. J Lipid Res 1985 26 : 1126 33.
8. Miettinen TA. Phytosterolaemia, xanthomatosis and premature atherosclerotic arterial disease: a case with high plant sterol absorption, impaired sterol elimination and low cholesterol synthesis. Eur J Clin Invest 1980 10 : 27 35.
9. Kolovou G, Voudris V, Drogari E et al. Coronary bypass grafts in a young girl with sitosterolemia. Eur Heart J 1996 17 : 965 6.
10. Mymin D, Wang J, Frohlich J, Hegele RA. Image in cardiovascular medicine. Aortic xanthomatosis with coronary ostial occlusion in a child homozygous for a nonsense mutation in ABCG8. Circulation 2003 107 : 791.
11. Solca C, Stanga Z, Pandit B et al. Sitosterolaemia in Switzerland: molecular genetics links the US Amish-Mennonites to their European roots. Clin Genet 2005 68 : 174 8.
12. Sudhop T, Lütjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002 106 : 1943 8.
13. Salen G, von Bergmann K, Lütjohann D et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004 109 : 966 71.
14. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 2001 3 (Suppl. E E11 6.
15. Connor WE, Lin DS, Pappu AS et al. Dietary sitostanol and campestanol: accumulation in the blood of humans with sitosterolemia and xanthomatosis and in rat tissues. Lipids 2005 40 : 919 23.
16. Lütjohann D, Brzezinka A, Barth E et al. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res 2002 43 : 1078 85.
17. Musliner T, Sirah W, Shah A et al. Long-term efficacy and safety profile of ezetimibe 10 mg in the treatment of patients with homozygous sitosterolemia: a multi-center, open-label, 2-year extension. Circulation 2007 116 : 93.
18. Nguyen LB, Salen G, Shefer S et al. Unexpected failure of bile acid malabsorption to stimulate cholesterol synthesis in sitosterolemia with xanthomatosis: comparison with lovastatin. Arteriosclerosis 1990 10 : 289 97.
19. Nguyen LB, Cobb M, Shefer S et al. Regulation of cholesterol biosynthesis in sitosterolemia: effects of lovastatin, cholestyramine, and dietary sterol restriction. J Lipid Res 1991 32 : 1941 8.
20. Bays HE, Moore PB, Drehobl MA et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001 23 : 1209 30.
21. Dujovne VA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002 90 : 1092 7.
22. Gagne C, Bays HE, Weiss SR et al. for the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002 90 : 1084 91.
23. van Heek M, Farley C, Compton DS et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001 134 : 409 17.
24. Knopp R, Bays H, Manion C. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atheroscler Suppl 2001 2 : 90.
25. Altmann SW, Davis HR Jr., Zhu LJ et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004 303 : 1201 4.
26. Davis HR Jr., Zhu LJ, Hoos LM et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004 279 : 33586 92.
27. Davies JP, Levy B, Ioannou YA. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 2000 65 : 137 45.
28. Temel RE, Tang W, Ma Y et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007 117 : 1968 78.
29. Miettinen TA, Gylling H. Plant stanol and sterol esters in prevention of cardiovascular diseases: a review. Int J Clin Pharmacol Ther 2006 44 : 247 50.
30. Koivunen-Niemela T, Parkkola K. Anatomy of the Achilles tendon (tendo calcaneus) with respect to tendon thickness measurements. Surg Radiol Anat 1995 17 : 263 8.
31. Salen G, Starc T, Sisk CM, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 2006 130 : 1853 7.
32. ZETIA® (ezetimibe). Prescribing Information. North Wales, PA : Merck/Schering Plough, 2006. PDR Electronic Library. http://www.thomsonhc.com/ pdrel/librarian (accessed May 2008).